Description:
IC50 Value: 5.0±0.7 mumol/l [1].
GW1929 is a synthetic peroxisome proliferator-activated receptor-γ (PPARγ) agonist,
in vitro: Using Ba2+ (10 mmol/l) as the charge carrier through VDCC, the half-inhibition constants (IC50) for GI 262570, GW 7845, GW 1929, and pioglitazone were 2.0 +/- 0.5, 3.0 +/- 0.5, 5.0 +/- 0.7, and 10.0 +/- 0.8 mumol/l, respectively [1]. PPARγ agonist GW1929significantly decreased TRPC1 and TRPC6 expression in PASMCs [2].
in vivo: GW1929treatment significantly attenuated the neurological damage in focal cerebral IR injury. Neuroprotective effects of GW1929 were found to be associated with significant reduction in the COX-2, iNOS, MMP-9, TNFα and IL-6 levels [3].GW1929treatment significantly ameliorated cerebral IR induced neurological symptoms, hyperlocomotion, cognitive deficits and hippocampal neuronal damage in CA1 hippocampus region in gerbils. Significant reduction in IR injury in